{"id":156124,"date":"2023-11-13T05:53:26","date_gmt":"2023-11-13T10:53:26","guid":{"rendered":"https:\/\/44.250.171.167\/?p=156124"},"modified":"2023-11-13T05:53:28","modified_gmt":"2023-11-13T10:53:28","slug":"marksans-pharma-limited-q2-fy24-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q2-fy24-earnings-conference-call-insights\/","title":{"rendered":"Marksans Pharma Limited Q2 FY24 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY24 Earnings Concall<\/strong><\/p>\n<ul>\n<li><strong>Financial Performance<\/strong>\n<ul>\n<li>Revenues grew 17% year-on-year to INR531 crores in Q2 FY&#8217;24.<\/li>\n<li>EBITDA up 41.9% year-on-year to INR113.9 crores in Q2.<\/li>\n<li>PAT grew 39.5% to INR83.9 crores in Q2.<\/li>\n<li>Gross margin improved 174 bps to 52.4% in Q2.<\/li>\n<li>For H1 FY&#8217;24, Revenue grew 16.4% year-on-year to INR1,031.3 crores.<\/li>\n<li>EBITDA grew 41% year-on-year to INR215.9 crores in H1.<\/li>\n<li>PAT grew 28.3% to INR154.3 crores in H1.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Operational Environment<\/strong>\n<ul>\n<li>Saw improved demand and volume growth across key markets.<\/li>\n<li>Pricing pressure normalized for Rx products in US.<\/li>\n<li>Reduction in raw material and freight rates vs last year.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Strategic Initiatives Progress<\/strong>\n<ul>\n<li>Received key product approvals from USFDA and UK MHRA.<\/li>\n<li>USFDA inspection completed with EIR status for Time-Cap Labs.<\/li>\n<li>On track with capacity expansion of acquired Teva unit.<\/li>\n<li>Passed recent audit by German health authorities.<\/li>\n<li>Strategic initiatives aimed at maximizing shareholder value.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Growth Outlook<\/strong>\n<ul>\n<li>Optimistic about driving growth.<\/li>\n<li>Focus remains on strengthening product pipeline.<\/li>\n<li>Expects revenue contribution from Teva unit to increase quarter-on-quarter.<\/li>\n<li>Hoping to sustain current strong margins in H2.<\/li>\n<li>Soft raw material and freight rates supportive.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Teva Facility Integration<\/strong>\n<ul>\n<li>Facility now operational but integration still ongoing.<\/li>\n<li>Investing to upgrade capacity.<\/li>\n<li>Expect full revenue potential from April 2024 onwards.<\/li>\n<\/ul>\n<\/li>\n<li><strong>New Product Launches<\/strong>\n<ul>\n<li>Received approvals for products like Esomeprazole.<\/li>\n<li>Launching in respective markets through distribution channels.<\/li>\n<li>Increases product portfolio and revenue generation.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Demand Trends<\/strong>\n<ul>\n<li>Growth drivers remain US and Europe markets.<\/li>\n<li>Expects this positive trend to continue in coming year.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Capital Allocation<\/strong>\n<ul>\n<li>Priority is expanding capacity at newly acquired Teva plant.<\/li>\n<li>Also exploring M&amp;A opportunities in Europe.<\/li>\n<li>Plans to expand geographies though nothing concrete yet.<\/li>\n<li>Will consider buyback or dividend based on free cash flow.<\/li>\n<\/ul>\n<\/li>\n<li><strong>ANDA Filing Targets<\/strong>\n<ul>\n<li>Targeting 4-5 ANDA filings per year in US.<\/li>\n<li>Targeting 15-20 product authorizations per year in Europe.<\/li>\n<li>Already working on 60-70 products for Europe filings.<\/li>\n<li>Working towards filing DMFs for backward integration.<\/li>\n<li>Optimistic to file by end of current financial year.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Revenue Mix<\/strong>\n<ul>\n<li>Largest segment is pain, followed by digestive and cough\/cold.<\/li>\n<li>Around 30% from prescription-related segments.<\/li>\n<li>Some brands in Australia and Dubai region.<\/li>\n<li>Active in e-commerce segment like Amazon.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Capex Outlook and R&amp;D Spending<\/strong>\n<ul>\n<li>INR80-100 crores capex planned for next 6-12 months. Currently at 1.6% of sales.<\/li>\n<li>Guidance of around 2% for FY25-26.<\/li>\n<li>Further capex possible later to expand capacity further.<\/li>\n<li>Plan to increase R&amp;D spending going forward.<\/li>\n<li>To support more ANDA filings and new product development.<\/li>\n<li>Expects gradual increase rather than significant jump.<\/li>\n<li>Tailwinds from raw material costs moderating.<\/li>\n<li>Future growth to be driven by operating leverage and expanding product portfolio.<\/li>\n<\/ul>\n<\/li>\n<li><strong>OTC Prescription Mix<\/strong>\n<ul>\n<li>Globally around 70% OTC, 30% prescription.<\/li>\n<li>US slightly higher OTC around 78%.<\/li>\n<li>UK has larger prescription share so averages to 70\/30.<\/li>\n<li>Expect mix to remain relatively stable next 3-5 years.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Branded Business Opportunities<\/strong>\n<ul>\n<li>Currently small part of major markets like US, UK, Europe.<\/li>\n<li>May explore brands but generics are main focus.<\/li>\n<li>India, parts of Europe better markets for branding.<\/li>\n<li>Could expand via M&amp;A which helps with costs, timelines.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY24 Earnings Concall Financial Performance Revenues grew 17% year-on-year to INR531 crores in Q2 FY&#8217;24. EBITDA up 41.9% year-on-year to INR113.9 crores in Q2. PAT grew 39.5% to INR83.9 crores in Q2. Gross margin improved 174 bps to 52.4% in Q2. For H1 FY&#8217;24, Revenue grew 16.4% [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":154818,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,1115],"class_list":["post-156124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170936,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":156124,"position":0},"title":"Marksans Pharma Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"September 4, 2025","format":false,"excerpt":"Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Presenting below are its Q1 FY26 earnings results. \u00a0 Q1 FY26 Earnings Results Revenue from Operations: \u20b9620 crores, up 5% YoY (Q1 FY25: \u20b9605.6 crores), and up 8.5% QoQ (Q4 FY25: \u20b9576.5 crores). Gross Profit:\u00a0\u20b9358.2 crores, up 8.9%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Marksans Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156192,"url":"https:\/\/alphastreet.com\/india\/nazara-technologies-ltd-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":156124,"position":1},"title":"Nazara Technologies Ltd Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 14, 2023","format":false,"excerpt":"Key highlights from Nazara Technologies Ltd (NAZARA) Q2 FY24 Earnings Concall Financial Performance Revenue increased 13% year-on-year to INR297.2 crores. EBITDA grew 30% year-on-year to INR 27.9 crores. PAT increased 53% year-on-year to INR 24.2 crores. Gaming segment revenue grew 43% and EBITDA 14% year-on-year in Q2. eSports segment revenue\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":138022,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":156124,"position":2},"title":"Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 25, 2022","format":false,"excerpt":"Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":154984,"url":"https:\/\/alphastreet.com\/india\/newgen-software-technologies-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":156124,"position":3},"title":"Newgen Software Technologies Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"October 17, 2023","format":false,"excerpt":"Key highlights from Newgen Software Technologies Limited (NEWGEN) Q2 FY24 Earnings Concall Revenue Growth Across Geographies Newgen witnessed robust 30% YoY revenue growth to INR293 crores in Q2 FY24. Strong growth seen in India region with 38% YoY growth; significant orders from public and private banks. EMEA region grew 34%\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":156074,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":156124,"position":4},"title":"Aurobindo Pharma Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2023","format":false,"excerpt":"Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q2 FY24 Earnings Concall Revenue Growth Revenue grew 25.8% year-on-year to INR7,219 crores, driven by growth across formulations, APIs, and geographies. Formulations revenue, excluding Puerto Rico, grew 29% YoY to INR5,968 crores. US formulations revenue, without Puerto Rico, grew 35.7% year-on-year to INR3,385\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":155907,"url":"https:\/\/alphastreet.com\/india\/reliance-industries-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":156124,"position":5},"title":"Reliance Industries Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 7, 2023","format":false,"excerpt":"Key highlights from Reliance Industries Limited (RELIANCE) Q2 FY24 Earnings Concall Financial Performance Q2 EBITDA reached record INR45,000 crores, up 30% YoY. Net profit grew 30% YoY to INR20,000 crores. Growth seen across consumer business, digital services, O2C and oil & gas. Retail Business Growth Retail revenues grew 19% YoY\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/156124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=156124"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/156124\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/154818"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=156124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=156124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=156124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}